Radial Versus Femoral Access for Carotid Artery Stenting in Patients With Carotid Artery Stenosis: Protocol of the Multicenter RACE-CAS Randomized Trial Authors: Rui Liu, Kang Yuan, Xuehan Liu, Wen Sun, Xianjun Huang, Hao Wang, Tingyu Yi, Xin Liu, Qin Yin, Ruidong Ye, Minmin Ma, Wusheng Zhu, Xinfeng Liu Published: 2026 ABSTRACT BACKGROUND:Carotid artery stenting (CAS) is conventionally performed via transfemoral access (TFA), which requires prolonged postoperative immobilization and is associated with access-site complications. Transradial access (TRA) has emerged as an alternative to TFA for suitable vessel caliber and improved patient comfort. However, high-quality evidence directly comparing TRA and TFA for CAS in patients with carotid artery stenosis is still lacking. This trial aims to determine whether TRA is noninferior to TFA in patients treated with CAS due to carotid artery stenosis.METHODS:The RACE-CAS (Radial Versus Femoral Access for Carotid Artery Stenting in Patients With Carotid-Artery Stenosis) is a prospective, randomized, open-label, blinded-end point, multicenter trial. Up to 3000 patients with carotid artery stenosis will be randomly assigned in a 1:1 ratio to receive CAS treatment via either TRA or TFA across 70 centers in China.RESULTS:The primary end point is the incidence of death, new-onset stroke, myocardial infarction, or severe hemorrhage events within 30 days post-procedure, analyzed in the full analysis set using risk differences with 2-sided 95% CIs for noninferiority testing. Key secondary outcomes include the successful rate of CAS and angiography, patient comfort, and each individual component of the primary end point within 48 hours or 30 days post-procedure. Safety outcomes include all adverse events and severe adverse events. The RACE-CAS trial enrolled its first patient on July 3, 2022, and recruitment is ongoing. At the time of manuscript submission, the sample size required for the first planned interim analysis had been completed.CONCLUSIONS:The RACE-CAS trial will provide definitive, high-level evidence on the comparative efficacy and safety of TRA versus TFA for carotid artery stenting in patients with carotid artery stenosis, with the goal of guiding clinical practice.REGISTRATION:URL: https://www.clinicaltrials.gov; Unique identifier: NCT05416853. CLINICAL PERSPECTIVE What Is New? The RACE-CAS trial (Radial Versus Femoral Access for Carotid Artery Stenting in Patients With Carotid-Artery Stenosis) is a prospective, multicenter, randomized study designed to compare the safety and efficacy of transradial versus transfemoral access for carotid artery stenting in patients with carotid artery stenosis. The RACE-CAS trial (Radial Versus Femoral Access for Carotid Artery Stenting in Patients With Carotid-Artery Stenosis) is a prospective, multicenter, randomized study designed to compare the safety and efficacy of transradial versus transfemoral access for carotid artery stenting in patients with carotid artery stenosis. What Are the Clinical Implications? If transradial access demonstrates comparable procedural safety and efficacy to transfemoral access, it may provide high-level evidence to support this alternative access strategy in clinical practice. If transradial access demonstrates comparable procedural safety and efficacy to transfemoral access, it may provide high-level evidence to support this alternative access strategy in clinical practice. Ischemic stroke is one of the leading causes of morbidity and mortality worldwide.1 Carotid artery stenosis represents a major risk factor for ischemic stroke.2 Carotid endarterectomy and carotid artery stenting (CAS) are the 2 most widely adopted interventions for stroke prevention in carotid artery stenosis.3,4 Although carotid endarterectomy remains the gold standard for carotid artery stenosis, it is associated with a nonnegligible risk of perioperative complications.5 Meanwhile, CAS has been adopted as a therapeutic alternative owing to its minimally invasive nature and comparable cardiovascular risk.6–9 CAS is traditionally performed via transfemoral access (TFA), which requires prolonged postoperative immobilization and is associated with various access-site complications.10 Therefore, further investigation of alternative vascular access approaches is warranted to reduce access-site complications and enhance the effectiveness of CAS for carotid artery stenosis. Transradial access (TRA) has been widely adopted as an alternative to TFA in percutaneous coronary interventions for its suitable caliber and sufficient collateral perfusion in the radial artery.11,12 However, the use of TRA in neurointervention surgeries is still at an early stage, and high-quality evidence remains limited. Clinical data suggest that TRA and TFA have comparable procedure time for cerebral angiography; however, TRA has a longer puncture time.13 In technically demanding procedures such as mechanical thrombectomy, TRA also has similar recanalization rates to TFA, with a slightly longer procedural time.14 The major complication of TRA is radial artery occlusion, with previously reported incidence rates ranging from 1% to 12%.15 Nevertheless, due to greater patient comfort and reduced requirements for postprocedural immobilization, TRA is often preferred by patients.16 However, these findings are largely derived from studies with limited sample sizes. Regarding the access site for CAS for carotid artery stenosis, current clinical guidelines have not yet provided specific recommendations on the choice between TRA and TFA, leaving neurointerventionalists without high-level evidence to guide the use of this alternative access site for CAS procedures. Therefore, the RACE-CAS (Radial Versus Femoral Access for Carotid Artery Stenting in Patients With Carotid-Artery Stenosis) randomized trial is designed and conducted to determine the efficacy and safety of TRA versus TFA for CAS in patients with carotid artery stenosis. Methods Data Availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Study Design The RACE-CAS trial is a multicenter, prospective, randomized, open-label, noninferiority trial, aiming to investigate the efficacy and safety of TRA versus TFA for CAS in patients with carotid artery stenosis across 70 centers in China. The flow chart is illustrated in the Figure, and the trial schedule is shown in the Table. The trial is designed in compliance with the Declaration of Helsinki and has been registered at https://www.clinicaltrials.gov (Unique identifier: NCT05416853). Trial-related injury insurance has been obtained for all participants. The protocol has been approved by the Clinical Trials Ethics Committee of The First Affiliated Hospital of University of Science and Technology of China and all participating hospitals before enrollment. Enrollment of the first patient began in June 2022. Table.Trial Schedule Trial Schedule Study flowchart. AE indicates adverse event; CT, computed tomography; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NASCET, North American Symptomatic Carotid Endarterectomy Trial; NIHSS, National Institutes of Health Stroke Scale; TFA, transfemoral access; and TRA, transradial access. Study Population Inclusion Criteria General Inclusion Criteria Age ≥18 years. Age ≥18 years. Clinical Inclusion Criteria Symptomatic stenosis: Patients had a transient ischemic attack, amaurosis, or minor nondisabling stroke involving the target carotid artery within 180 days before randomization. Symptomatic stenosis: Patients had a transient ischemic attack, amaurosis, or minor nondisabling stroke involving the target carotid artery within 180 days before randomization. Asymptomatic stenosis: The results of medical history, physical examination, and neurological examination do not suggest ischemic symptoms in the target carotid artery. If the artery stenosis degree reaches the standard, there are any ≥1 of the following symptoms, including noncarotid artery symptoms, contralateral carotid artery symptoms, time from symptom to randomization >180 days, and vertebrobasilar artery symptoms. Asymptomatic stenosis: The results of medical history, physical examination, and neurological examination do not suggest ischemic symptoms in the target carotid artery. If the artery stenosis degree reaches the standard, there are any ≥1 of the following symptoms, including noncarotid artery symptoms, contralateral carotid artery symptoms, time from symptom to randomization >180 days, and vertebrobasilar artery symptoms. Pulsation is palpable in the radial and femoral arteries, and the radial artery must meet any of the following criteria: the Allen test or the Barbeau test suggesting that ulnar artery collateral circulation is good, or preoperative ultrasound confirming that the radial artery and ulnar artery are well developed. Pulsation is palpable in the radial and femoral arteries, and the radial artery must meet any of the following criteria: the Allen test or the Barbeau test suggesting that ulnar artery collateral circulation is good, or preoperative ultrasound confirming that the radial artery and ulnar artery are well developed. No family planning within half 1 year after informed consent is signed or a negative pregnancy test for women with childbearing potential. No family planning within half 1 year after informed consent is signed or a negative pregnancy test for women with childbearing potential. Patients or their guardians can understand the study purpose, voluntarily participate in the trial, sign informed consent, and complete follow-up visits. Patients or their guardians can understand the study purpose, voluntarily participate in the trial, sign informed consent, and complete follow-up visits. Vascular Inclusion Criteria Lesions located in the internal carotid artery with or without involvement of the adjacent common carotid artery. Lesions located in the internal carotid artery with or without involvement of the adjacent common carotid artery. For symptomatic patients, at least 1 of the following conditions should be met: stenosis of ≥70% on ultrasonography, ≥70% on computed tomography angiography or magnetic resonance angiography, and ≥50% on digital subtraction angiography according to NASCET (North American Symptomatic Carotid Endarterectomy Trial) standard. For symptomatic patients, at least 1 of the following conditions should be met: stenosis of ≥70% on ultrasonography, ≥70% on computed tomography angiography or magnetic resonance angiography, and ≥50% on digital subtraction angiography according to NASCET (North American Symptomatic Carotid Endarterectomy Trial) standard. For asymptomatic patients, at least 1 of the following conditions should be met: stenosis of ≥70% on ultrasonography, ≥80% on computed tomography angiography or magnetic resonance angiography, and ≥60% on digital subtraction angiography according to NASCET standard. For asymptomatic patients, at least 1 of the following conditions should be met: stenosis of ≥70% on ultrasonography, ≥80% on computed tomography angiography or magnetic resonance angiography, and ≥60% on digital subtraction angiography according to NASCET standard. When bilateral carotid stenosis is present, only one unilateral carotid artery can be treated. The other carotid artery, as a nonstudy artery, should be dealt with 30 days before randomization or 30 days after treatment. When bilateral carotid stenosis is present, only one unilateral carotid artery can be treated. The other carotid artery, as a nonstudy artery, should be dealt with 30 days before randomization or 30 days after treatment. According to clinician experience, the operation access would be reasonable, and the surgical instruments could be successfully delivered to the lesion site. According to clinician experience, the operation access would be reasonable, and the surgical instruments could be successfully delivered to the lesion site. Exclusion Criteria General Exclusion Criteria Progressive stroke. Progressive stroke. Allergic to drugs associated with CAS, such as lidocaine, aspirin, and clopidogrel. Allergic to drugs associated with CAS, such as lidocaine, aspirin, and clopidogrel. Allergic to contrast media or interventional devices. Allergic to contrast media or interventional devices. Any active hemorrhage, severe anemia, coagulation disorders, or unnecessary blood transfusion treatment. Meet at least 1 of the following laboratory tests before randomization: hemoglobin <100g/L, or platelet count <100*10^9/L, or unadjusted international normalized ratio >1.5, or prothrombin time beyond the upper limit of normal for 1 minute, or heparin-induced thrombocytopenia. Any active hemorrhage, severe anemia, coagulation disorders, or unnecessary blood transfusion treatment. Meet at least 1 of the following laboratory tests before randomization: hemoglobin <100g/L, or platelet count <100*10^9/L, or unadjusted international normalized ratio >1.5, or prothrombin time beyond the upper limit of normal for 1 minute, or heparin-induced thrombocytopenia. Previous ipsilateral large cerebral infarction stroke with sequelae, which can affect the judgment of the study end point. Previous ipsilateral large cerebral infarction stroke with sequelae, which can affect the judgment of the study end point. Severe cognitive disorder, unable to cooperate with treatment or postoperative evaluation. Severe cognitive disorder, unable to cooperate with treatment or postoperative evaluation. Spontaneous intracranial hemorrhage occurred 12 months before informed consent was written. Ischemic stroke hemorrhage transformation occurred 3 months before informed consent was signed. Spontaneous intracranial hemorrhage occurred 12 months before informed consent was written. Ischemic stroke hemorrhage transformation occurred 3 months before informed consent was signed. A new-onset stroke occurred 7 days before informed consent was signed, which has a high hemorrhagic transformation risk after preoperative imaging evaluation. A new-onset stroke occurred 7 days before informed consent was signed, which has a high hemorrhagic transformation risk after preoperative imaging evaluation. Any condition that could interfere with digital subtraction angiography or make percutaneous arterial access unsafe. Any condition that could interfere with digital subtraction angiography or make percutaneous arterial access unsafe. Neurological disorders that occurred 2 years before informed consent was signed, which have transient or fixed neurological deficits, cannot be distinguished from transient ischemic attack or stroke. Neurological disorders that occurred 2 years before informed consent was signed, which have transient or fixed neurological deficits, cannot be distinguished from transient ischemic attack or stroke. Participating in other clinical trials. Participating in other clinical trials. Myocardial infarction within 30 days before informed consent was signed. Myocardial infarction within 30 days before informed consent was signed. Intolerance to neurointerventional surgery, for example, coronary artery stenosis ≥70% without or unable to revascularization, ejection fraction <30% or New York Heart Association classification ≥class III, stable angina pectoris (static angina pectoris with ECG changes), organ transplantation (such as heart, lung, liver, and kidney) planned or under evaluation, malignant tumor or respiratory insufficiency making life expectancy <5 years or forced expiratory volume in 1 second <30% (prediction), dialysis-dependent renal failure, and poorly controlled diabetes (fast serum glucose >400 mg/dL and urine ketone >2). Intolerance to neurointerventional surgery, for example, coronary artery stenosis ≥70% without or unable to revascularization, ejection fraction <30% or New York Heart Association classification ≥class III, stable angina pectoris (static angina pectoris with ECG changes), organ transplantation (such as heart, lung, liver, and kidney) planned or under evaluation, malignant tumor or respiratory insufficiency making life expectancy <5 years or forced expiratory volume in 1 second <30% (prediction), dialysis-dependent renal failure, and poorly controlled diabetes (fast serum glucose >400 mg/dL and urine ketone >2). Diseases or anatomic features that would contraindicate CAS, such as pathway problems caused by cervical radiation therapy, and cervical space-occupying lesion compressing carotid artery. Diseases or anatomic features that would contraindicate CAS, such as pathway problems caused by cervical radiation therapy, and cervical space-occupying lesion compressing carotid artery. Disease or anatomic features that make it difficult for radial or femoral artery puncture and sheath insertion or instrument passage, such as local infection, abnormal anatomic development confirmed by ultrasound or other imaging examination, previous interventional or open surgery, and the instrument delivery, cannot be completed. Disease or anatomic features that make it difficult for radial or femoral artery puncture and sheath insertion or instrument passage, such as local infection, abnormal anatomic development confirmed by ultrasound or other imaging examination, previous interventional or open surgery, and the instrument delivery, cannot be completed. Vascular Exclusion Criteria Severe vascular tortuosity or dissection that influence catheters delivering. Severe vascular tortuosity or dissection that influence catheters delivering. Stenting, balloon dilation, or coiling was performed in ipsilateral vessels in the past. Stenting, balloon dilation, or coiling was performed in ipsilateral vessels in the past. Extensive or diffuse atherosclerotic disease involving the aortic arch and the proximal common carotid artery, which would influence catheter delivery. Extensive or diffuse atherosclerotic disease involving the aortic arch and the proximal common carotid artery, which would influence catheter delivery. Besides the target vessel, there are also ipsilateral intracranial or extracranial arteries stenosis larger than the target lesion, aneurysms with the longest diameter ≥5-mm cerebrovascular arteriovenous malformation, or other cerebrovascular disease with abnormal cerebral angiography. Besides the target vessel, there are also ipsilateral intracranial or extracranial arteries stenosis larger than the target lesion, aneurysms with the longest diameter ≥5-mm cerebrovascular arteriovenous malformation, or other cerebrovascular disease with abnormal cerebral angiography. Ipsilateral carotid artery chronic occlusions. Ipsilateral carotid artery chronic occlusions. Plan to perform endovascular treatment of other arteries at the same time, including vertebral arteries. Plan to perform endovascular treatment of other arteries at the same time, including vertebral arteries. Randomization and Masking The RACE-CAS trial uses a stratified block randomization method for randomization. Randomization will be stratified by age (≥18 and <75 versus ≥75 years), symptomatic stenosis (yes versus no), and lesion vascular location (left versus right). A centralized Web-based randomization platform, implemented through an Interactive Web Response System, will be used to perform treatment allocations. The randomization schedule will be generated by computer using SAS, version 9.4, with an equal allocation ratio between the TRA and TFA groups and embedded within the system. After confirmation of eligibility, the enrolling investigator will log into the Interactive Web Response System to receive the assigned access strategy in real time, thereby maintaining allocation concealment throughout the enrollment process. Before recruiting participating centers, a questionnaire will be distributed to physicians to assess their procedural volumes. Eligibility criteria for operators include prior experience of at least 50 CAS procedures via the TFA and at least 30 procedures using TRA before participation in the trial. Participating centers are required to perform at least 50 CAS procedures per year. Because the selection of TRA or TFA must be determined at the time of CAS, blinding of the interventional operators is not feasible; therefore, the RACE-CAS trial is designed as an open-label study. To preserve study integrity and minimize bias, access to treatment allocation is restricted to designated unblinded personnel directly involved in the CAS procedure. These individuals are required to maintain strict confidentiality and are prohibited from disclosing allocation information. All other investigators, such as outcome assessment, participants, and statistical analysts, will remain blinded to treatment assignment and will have no access to allocation-related documents throughout the study period. Treatments Before the procedure, patients will undergo appropriate preoperative imaging evaluation to assess the severity and anatomic characteristics of carotid artery stenosis. Participants randomized to the intervention arms will undergo CAS via either TRA or TFA according to the assigned treatment group. After successful arterial access and sheath placement, angiography of the aortic arch and target carotid artery will be performed. Under fluoroscopic guidance, the catheter system will then be advanced to engage the target carotid artery. The stenotic lesion will be treated with carotid artery stent deployment, with the use of embolic protection devices. Commonly used embolic protection devices include SpiderFX, Emboshield NAV6, FilterWire EZ, and so on. Postdilation may be performed to optimize stent expansion. Hemodynamic parameters and neurological status will be continuously monitored throughout the procedure. At the completion of the intervention, all devices will be withdrawn, and hemostasis will be achieved according to standard institutional protocols. All participating centers and operators are required to follow current guideline-recommended standards of care for CAS. The detailed puncture techniques for each treatment group are described below. TRA Group For patients assigned to the TRA group, vascular access will be obtained via the radial artery. The right radial artery is generally preferred, with either the proximal radial artery or the distal radial artery selected at the operator’s discretion. After identification of the puncture site, arterial access will be established using a through-and-through suture technique or a modified Seldinger technique, followed by placement of a 6F arterial sheath or a 7F thin-walled sheath to facilitate the endovascular procedure. If puncture failure or procedural difficulty occurs due to factors such as lesion complexity, unfavorable vascular anatomy, or vasospasm, a change in the puncture site (such as contralateral radial artery or femoral artery) is permitted. TFA Group For patients assigned to the TFA group, vascular access will be established via the femoral artery, with the right femoral artery preferentially selected to facilitate intraprocedural manipulation. After identification of the puncture site, a 5- to 10-mm skin incision will be made inferior to the intended puncture point to allow smooth passage of the arterial sheath or vascular closure device. Arterial access will then be obtained using the modified Seldinger technique, followed by insertion of a 6F to 8F thin-walled sheath to facilitate the endovascular procedure. If puncture failure or procedural difficulty occurs due to factors such as lesion complexity, unfavorable vascular anatomy, or vasospasm, a change in the puncture site (such as radial artery or contralateral femoral artery) is permitted. Efficacy End Points Primary End Points The primary end point is the incidence of death, new-onset stroke, myocardial infarction, or severe hemorrhage events within 30 days post-procedure. The composite end point event is defined as any one of death, new-onset stroke, myocardial infarction, and severe hemorrhage events within 30 days. Details of the definition were provided in Table S1. Secondary End Points The incidence of death, new-onset stroke, myocardial infarction, or severe hemorrhage events within 48 hours post-procedure. The incidence of death, new-onset stroke, myocardial infarction, or severe hemorrhage events within 48 hours post-procedure. Success rate of cerebral angiography. Success rate of cerebral angiography. Success rate of CAS. Success rate of CAS. Degree of patient-reported comfort measured by the simplified General Comfort Questionnaire at 5 to 7 days. Degree of patient-reported comfort measured by the simplified General Comfort Questionnaire at 5 to 7 days. Time from arterial puncture to completion of digital subtraction angiography or CAS. Time from arterial puncture to completion of digital subtraction angiography or CAS. The National Institutes of Health Stroke Scale score changes within 5 to 7 days post-procedure. The National Institutes of Health Stroke Scale score changes within 5 to 7 days post-procedure. The modified Rankin Scale score at 30 ± 7 days post-procedure. The modified Rankin Scale score at 30 ± 7 days post-procedure. Tertiary End Points The incidence of death, new-onset stroke, and myocardial infarction within 48 hours/30 days post-procedure. The incidence of death, new-onset stroke, and myocardial infarction within 48 hours/30 days post-procedure. The incidence of death within 48 hours/30 days post-procedure. The incidence of death within 48 hours/30 days post-procedure. The incidence of new-onset stroke within 48 hours/30 days post-procedure. The incidence of new-onset stroke within 48 hours/30 days post-procedure. The incidence of myocardial infarction within 48 hours/30 days post-procedure. The incidence of myocardial infarction within 48 hours/30 days post-procedure. The incidence of severe hemorrhage events within 48 hours/30 days post-procedure. The incidence of severe hemorrhage events within 48 hours/30 days post-procedure. X-ray exposure. X-ray exposure. Safety End Points Proportion of all adverse events (AEs). Proportion of all adverse events (AEs). Proportion of severe AEs. Proportion of severe AEs. Proportion of AEs related to operation and device. Proportion of AEs related to operation and device. Incidence of AEs of special interest including (1) pseudoaneurysms requiring ultrasound-guided compression or thrombin injections or surgical treatment, (2) hematoma requiring prolonged hospital stay, (3) limb ischemia and nerve injury adjacent to the blood vessels, and (4) radial artery occlusion or thrombosis confirmed by ultrasound. Incidence of AEs of special interest including (1) pseudoaneurysms requiring ultrasound-guided compression or thrombin injections or surgical treatment, (2) hematoma requiring prolonged hospital stay, (3) limb ischemia and nerve injury adjacent to the blood vessels, and (4) radial artery occlusion or thrombosis confirmed by ultrasound. Data and Safety Monitoring Board An independent data and safety monitoring board will be constituted, consisting of 3 members with expertise in neurology, neurointervention, and biostatistics. All data and safety monitoring board members will be independent of the study sponsor and will not participate in trial conduct. The board will meet on an annual basis to oversee trial progress and to review reports of serious AEs to safeguard participant safety. The data and safety monitoring board will have access to unblinded safety and efficacy data and will be authorized to issue confidential recommendations to the trial steering committee regarding continuation, modification, or early termination of the study based on its evaluations. Amendments of the protocol were listed in Table S2. Sample Size Estimate According to the previous randomized controlled trials and retrospective studies,6,17–20 the composite end point occurred in ≈3% of patients treated with CAS. Taking the available evidence together with expert clinical judgment, the event rate for the primary outcome was conservatively assumed to be 3% in the TFA group. To address the primary objective using a noninferiority design with a predefined margin of 2% for the risk difference between the TRA and TFA group, which was established based on previous comparative studies of TRA versus TFA,21 the required sample size was estimated to be 2690 participants under the following assumptions: (1) a 2-sided overall type I error rate of 0.05, (2) a statistical power of 80%, and (3) 2 planned interim analyses conducted after 33.3% and 66.6% of participants had been enrolled. The overall type I error rate will be controlled using the Pocock alpha-spending function. Accordingly, a 1-sided significance level of 0.011 will be applied at each interim analysis and the final analysis. Allowing for an anticipated dropout rate of 10% consisting of loss to follow-up or crossover/protocol nonadherence, and assuming a 1:1 allocation between the 2 treatment groups, a total of 3000 participants will be enrolled, comprising 1500 participants assigned to the TRA group and 1500 to the TFA group. Sample size estimation is performed based on PASS (NCSS, LLC, Kaysville), version 15.0. Statistical Analyses The primary outcome will be analyzed in the full analysis set, with patients analyzed according to the intention-to-treat principle. The efficacy analysis will also be performed at the per-protocol set, defined as participants without major protocol violations, and the as-treated set. The primary outcome will be analyzed using complete cases without imputation for missing data and will follow the treatment groups assigned at randomization, irrespective of crossover, or treatment modification. The between-group difference in primary outcome rates (TRA minus TFA) will be estimated and presented with 2-sided 95% CI, calculated using the Newcombe-Wilson method. For noninferiority testing, the Farrington-Manning method for risk differences will be used. At each interim and final analysis, noninferiority will be concluded if both of the following prespecified criteria are met: (1) the upper bound of the 2-sided 97.8% CI for the between-group difference in the primary outcome is <2.0% and (2) the corresponding 1-sided Farrington-Manning P value is <0.011 (according to Pocock-adjusted). If these criteria are satisfied at any analysis stage, the trial will be considered to have demonstrated overall noninferiority, and early termination for noninferiority may be considered according to the prespecified group-sequential monitoring plan. Sensitivity analyses will be conducted to assess the robustness of the primary noninferiority conclusion under alternative analytical assumptions, including different analysis populations and analytic approaches. Detailed specifications of sensitivity analyses will be prespecified in the statistical analysis plan finalized before database lock. Secondary outcomes (eg, composite end points at 48 hours, successful rate of CAS, and patient comfort) will be evaluated using appropriate statistical models, including ordinal logistic regression, linear regression, or modified Poisson regression, as appropriate. The crossover rate from TRA to TFA and from TFA to TRA, together with the reasons for crossover, will be reported separately. In addition, subgroup analyses will be conducted to explore potential interactions between the primary outcome and predefined subgroups. Subgroup analyses will be based on stratified variables, such as sex (male versus female), smoking (yes or no), hypertension (yes or no), diabetes (yes or no), coronary heart disease (yes or no), hyperlipidemia (yes or no), preoperative cerebral angiography (yes or no), and puncture site on the first attempt (left or right). Statistical analyses were implemented in R (version 4.2.1, R Core Team, Vienna, Austria). A 2-sided P<0.05 will be considered statistically significant for the final analysis of the primary end point, respecting the adjusted alpha boundaries for interim looks. Discussion The RACE-CAS trial is a multicenter, randomized study designed to evaluate whether TRA is noninferior to TFA for CAS in patients with carotid artery stenosis, which may provide high-level evidence to support this alternative access strategy in clinical practice. TRA has been suggested as a safe and feasible alternative for most neurointerventional procedures.22,23 Clinical trials have demonstrated that TRA is noninferior to TFA in terms of procedural success and complication rates for cerebral angiography16 and mechanical thrombectomy.14 Meta-analyses supported that TRA has fewer access-site complications than TFA.24 Nevertheless, the use of TRA in CAS remains controversial. Although CAS via radial access achieves high success rates,25 crossover from TRA to TFA occurs more frequently due to failed puncture or anatomical reasons.26 In addition, radial artery occlusion remains a potential concern with TRA, with reported incidence rates ranging from 1% to 12%.15 To address this problem, the present study aimed to compare the efficacy and safety of CAS through TRA and TFA in patients with carotid artery stenosis. The RACE-CAS trial is designed to address a key clinical question: whether TRA is noninferior to TFA for CAS. We adopt broad inclusion criteria to enhance generalizability and to facilitate the wider application of TRA in clinical practice. Meanwhile, participants were excluded for the following reasons. First, because ulnar artery patency may affect the feasibility of TRA, we excluded inadequate radial artery circulation. Second, participants with severe vascular tortuosity or anatomic variations were excluded to avoid the influence of procedure failure on the assessment of access-site–related outcomes. Third, key safety exclusions, such as known allergic reactions, ipsilateral large cerebral infarction, and coagulation disorders, were applied to mitigate CAS-related risks and to allow a clearer comparison of the 2 access strategies under optimized conditions. A key design consideration is the open-label nature of the CAS surgery, necessitated by the need for neurointerventionalists to select either TRA or TFA. To minimize assessment bias, rigorous blinding procedures were implemented for outcome assessors, follow-up staff, and statisticians. Furthermore, the trial incorporates 2 interim analyses conducted by an independent data and safety monitoring board and adjustment for stratification factors, all of which serve to strengthen the validity of the final conclusions. In addition, the present trial was primarily designed as an access-site–related trial focusing on peri-procedural safety and technical outcomes associated with TRA versus TFA for CAS. Therefore, the 30-day follow-up period was selected to capture the majority of access-site complications and early procedural AEs, which are the primary outcome in this study. Patients were excluded if they had conditions affecting vascular access (eg, small radial artery diameter, severe femoral atherosclerosis, and prior vascular intervention) or unfavorable anatomy hindering catheterization and device delivery (eg, complex aortic arch, severe vascular tortuosity, and unfavorable vessel angulation). Aortic arch anatomy and arch type were critical determinants of procedural success for CAS via different access sites. However, given the interplay of multiple confounding factors, it was not feasible to establish a specific aortic arch type as an absolute exclusion criterion. Therefore, enrollment eligibility was determined based on the operator’s preprocedural clinical judgment regarding the feasibility and safety of CAS via both the TRA and TFA during the screening stage, which may exclude patients with particularly challenging vascular anatomy. As a result, the study population may represent patients who were suitable candidates for either access strategy, and the generalizability of our findings to the access-site selection in the overall CAS population may be limited. The RACE-CAS trial enrolled its first patient on July 3, 2022, and recruitment is ongoing. At the time of manuscript submission, the sample size required for the first planned interim analysis had been completed. The final sample size should be considered when interpreting the results of this noninferiority trial. Although the currently achieved enrollment fulfilled the requirement for the prespecified interim analysis, a smaller-than-planned sample size may reduce statistical power and widen CIs around the estimated treatment effect. ARTICLE INFORMATION Sources of Funding The project is supported by the Program for Innovative Research Team of The First Affiliated Hospital of University of Science and Technology of China (IHM No. 2023IHM01050) and the National Natural Science Foundation of China (grants NSFC-82471341 and NSFC-U22A20341). Disclosures None. Supplemental Material Tables S1–S3 Supplementary Material